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Table A1 
PRICE SCENARIOS 
  Price in EUR
 Study 1 1 2 3 4 5 Replication of 2nd Scenario
 Hazelnut spread       
L Zentis Nusspli 1.43 1.48   1.53   1.58   1.63   1.48   
M Nutella 1.90   1.85   1.80   1.75   1.70   1.85   
H Nudossi 2.51   2.55   2.60   2.61   2.65   2.55   
 Headphones       
L Sony MDRZX100B 17.90  18.40  19.90  21.40  22.90   18.40   
M Sony MDRZX300B 35.90  34.40  32.90  31.40  29.90   34.40   
H Sony MDRZX600B 49.49  50.99  52.49  53.99  55.49   50.99   
 Ketchup       
L K classic 0.71   0.78   0.85   0.92   0.99   0.78   
M Kraft 1.52   1.45   1.38   1.31   1.24   1.45   
H Heinz 1.79   1.86   1.90   1.96   1.99   1.86   
 Mulled wine       
L Oma‘s 1.13   1.15   1.17   1.19   1.21   1.15   
M Christkindl 1.35   1.32   1.30   1.28   1.25   1.32   
H Nürnberger Christkindl Markt 2.24   2.26   2.28   2.30   2.20   2.26   
 Study 2 1 2 3 4 5 Replication of 2nd Scenario
 Chips       
L Gut & Günstig Paprika 1.04   1.09   1.14   1.19   1.24   1.09   
M Lorenz Chipsletten Paprika 1.50   1.45   1.40   1.35   1.30   1.45   
H Pringles Original 1.73   1.75   1.83   1.85   1.93   1.75   
 Toothpaste       
L Signal Kariesschutz 0.60   0.67   0.70   0.72   0.75   0.67   
M Odol Med3 Original 0.80   0.79   0.78   0.77   0.76   0.79   
H Elmex Sensitive 2.50   2.52   2.57   2.62   2.67   2.52   
 Study3 1 2 3 4 5 Replication of 2nd Scenario
 Headphones       
L2 Sony MDR-V150 17.60  18.70  19.60  21.70  22.60   18.70   
L Sony MDRZX300B  17.90  18.40  19.90  21.40  22.90   18.40   
M Sony MDRZX400B 35.90  34.40  32.90  31.40  29.90   34.40   
 Hazelnut spread       
L2 Schoko mac 1.43   1.43   1.58   1.53   1.68   1.43   
L Zentis Nusspli 1.43   1.48   1.53   1.58   1.63   1.48   
M Nutella 1.90   1.85   1.80   1.75   1.70   1.85   
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PRICE SCENARIOS (STUDIES 1 – 4) 
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Table A1 (Continued) 
PRICE SCENARIOS 
  Price in EUR
 Study 4a 1 2 3 4 5 Replication of 2nd Scenario
 Chips       
L Gut & Günstig Paprika 1.04 1.08 1.12 1.16 1.20 1.08 
M Lorenz Chipsletten Paprika 1.43 1.39 1.35 1.31 1.27 1.39 
H Pringles Original 1.73 1.75 1.83 1.85 1.93 1.75 
 Ketchup       
L K classic 0.71   0.78   0.85   0.92   0.99   0.78   
M Kraft 1.52   1.45   1.38   1.31   1.24   1.45   
H Heinz 1.79   1.86   1.90   1.96   1.99   1.86   
 Toothpaste       
L Signal Kariesschutz 0.75 0.76 0.77 0.78 0.79 0.76 
M blend-a-med complete plus 0.85 0.84 0.83 0.82 0.81 0.84 
H Elmex Sensitive 2.45 2.52 2.4 2.55 2.35 2.52 
 Study 4b 1 2 3 4 5 Replication of 2nd Scenario
 Hazelnut spread       
L Zentis Nusspli 1.43 1.48   1.53   1.58   1.63   1.48   
M Nutella 1.90   1.85   1.80   1.75   1.70   1.85   
H Nudossi 2.51   2.55   2.60   2.61   2.65   2.55   
 Mouthwashes       
L K classic 0.86 1.01 1.16 1.31 1.46 1.01 
M Odol Med3 2.69 2.54 2.39 2.24 2.09 2.54 
H Listerine Total Care 3.56 3.60 3.65 3.50 3.46 3.60 
Price scenarios across product categories were randomly allocated to different versions of the paper and pen 
questionnaire to avoid order and position effects. We matched these different versions between the placebo and the 
treatment groups to make both conditions comparable. 
 
 
Figure A1 illustrates the design principles underlying the price scenarios used in all the 
studies. In each price scenario, the price of the compromise option M—which serves as the 
target option for our manipulation of the choice sets—was between the L and H prices. For 
each product category, we increased the trade-off difficulty between L and M from scenario 1 
to scenario 5 by successively increasing the price for L and decreasing the price for M. This 
was done in the binary sets as well as the trinary sets. The prices for option H in the trinary 
sets were always higher than for L and M, but were not varied according to a clear trend (see 
Table A1). 
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Figure A1 
ILLUSTRATION OF THE PRICE SCENARIO DESIGNS (STUDIES 1 – 4) 
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To measure their risk attitude in the financial domain, subjects participated in a lottery choice 
task where they were shown a series of lottery pairs (Holt and Laury 2002). Subjects had to 
choose between a less risky lottery A (with a small payoff variance but a low initial expected 
value) and a risky lottery B (with a greater payoff variance but a high initial expected value). 
The lottery pairs included a systematic trade-off between the two lottery types, as the 
expected payoff of the less risky lottery A increased, whereas the expected payoff of the risky 
lottery B decreased from early to later decisions (Table A2). Accordingly, the subjects started 
by choosing lottery B (risky) based on the much higher initial expected value (189 points 
compared to 49 points for lottery A) in their first decisions and switched to the (less risky) A 
lottery in the later decisions when the expected value of lottery A approached that of lottery B 
(Holt and Laury 2002). The point where a subject switched from the risky lottery B to the less 
risky lottery A is a measure of his risk attitude: a risk-neutral individual is expected to solely 
base his decision on the expected payoffs of the two lotteries and is therefore assumed to 
switch from B to A exactly when the expected value of lottery A exceeds the expected value 
of lottery B. In contrast, a risk-averse decision maker is expected to switch earlier due to the 
smaller variance in the decision outcomes inherent in the A lotteries. The later a participant 
switches from the risky lottery B to the less risky lottery A, the less risk-averse this participant 
is. Incentive compatibility of the procedure was ensured by randomly drawing one of the 
participant’s lottery decisions to become payoff relevant. 
 
Web Appendix II 
LOTTERY PROCEDURE – RISK ASSESSMENT IN THE FINANCIAL DOMAIN 
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Table A2 
LOTTERY DESIGN 
 
 
Which lottery do you prefer in each row?  
   Lottery Lottery A  Lottery B A B indifferent
1 [130, (10%); 40, (90%)]  [210, (90%); 0, (10%)]       
2 [130, (20%); 40, (80%)]  [210, (80%); 0, (20%)]       
3 [130, (30%); 40, (70%)]  [210, (70%); 0, (30%)]       
4 [130, (40%); 40, (60%)]  [210, (60%); 0, (40%)]       
5 [130, (50%); 40, (50%)]  [210, (50%); 0, (50%)]       
6 [130, (60%); 40, (40%)]  [210, (40%); 0, (60%)]       
7 [130, (70%); 40, (30%)]  [210, (30%); 0, (70%)]       
8 [130, (80%); 40, (20%)]  [210, (20%); 0, (80%)]       
9 [130, (90%); 40, (10%)]  [210, (10%); 0, (90%)]       
Note:  Decision #6, printed in bold, describes the choice in which risk neutral individuals are expected to 
switch from lottery B to lottery A. 
Participants were introduced that one point in all of the lotteries above equals five Euro cents. 
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In study 1, we found no significant differences between subjects in the treatment and the 
placebo group in terms of age in years (MTreatment=19.91, SDTreatment=2.19 vs. MPlacebo=19.88, 
SDPlacebo=1.26; t(45)=0.07, p=0.942), height in cm (MTreatment=182.30, SDTreatment=7.13 vs. 
MPlacebo=181.00, SDPlacebo=7.18; t(45)=0.63, p=0.535), weight in kg (MTreatment=77.70, 
SDTreatment=9.77 vs. MPlacebo=73.58, SDPlacebo=8.89; t(45)=1.51, p=0.138), and monthly net 
income in EUR (MTreatment=433.18, SDTreatment=288.48 vs. MPlacebo=486.43, SDPlacebo=259.95; 
t(43)=-0.65, p=0.518). Following Fern and Monroe (1996), we also compared subjects’ quality 
(versus price) orientation across all product categories, and subjects’ aided brand awareness of 
all products, but found no significant differences. Subjects do not differ in terms of quality 
(versus price) orientation for hazelnut spread (MTreatment=3.05, SDTreatment=0.59 vs. 
MPlacebo=3.05, SDPlacebo=0.90; t(Welch, 36.43)=0.09, p=0.993), headphones (MTreatment=3.00, 
SDTreatment=0.54 vs. MPlacebo=3.10, SDPlacebo=0.79; t(Welch, 32.74)=-0.45, p=0.658), ketchup 
(MTreatment=2.50, SDTreatment=0.80 vs. MPlacebo=2.67, SDPlacebo=1.01;  
t(44)=-0.62, p=0.540), and mulled wine (MTreatment=2.75, SDTreatment=0.86 vs. MPlacebo=2.44, 
SDPlacebo=0.86; t(32)=1.04, p=0.307). Likewise, subjects do not differ in aided brand awareness 
as indicated by a series of Fisher’s exact tests for hazelnut spread (p=1), headphones 
(p=0.609), ketchup (p=1.000), and mulled wine (p=0.898). 
 We tested whether ATD affected subjects’ mood, which, in turn, could have an effect 
on their buying behavior (Gardner 1985; Strack, Werth’, and Deutsch 2006). We first 
analyzed the MDMQ dimensions’ internal consistency reliabilities, which yielded satisfactory 
values between 0.78 (calmness) and 0.94 (wakefulness). Evaluation of the construct 
measures’ convergent validity yielded average variance extracted values of between 0.47 
(wakefulness) and 0.71 (calmness). Furthermore, discriminant validity was established as all 
three dimensions shared more variance with their associated items than with the other two 
Web Appendix III 
PRE-ANALYSIS OF STUDIES 1 – 4  
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constructs (Fornell and Larcker 1981). Next, we compared the MDMQ scores within the 
subjects (pre- versus post-treatment exposure) and between the two groups. To test for 
differences, we established mixed-effect general linear models, using a separate model for 
each of the three MDMQ dimensions.  
We defined the pleasantness scores of the pre- and post-exposure as a within-subjects 
factor and the experimental condition (treatment vs. placebo) as a between-subjects factor. 
We built analogous models for the wakefulness and calmness dimensions. The results 
revealed no significant differences between the treatment and placebo groups (pleasantness: 
F(1;44)0.12, p=0.735; wakefulness: F(1;44)1.05, p=0.312; calmness: F(1;42)0.29, p=0.595). 
Similarly, there were no significant differences between pre- and post-exposure (within) in the 
pleasantness (F(1;44)0.17, p=0.682) and wakefulness (F(1;44)2.08, p=0.156) dimensions, and 
only a slight significance at the 10 percent level in the calmness (F(1;42)3.48, p=0.069) 
dimension. Finally, we found no significant differences in the change of mood dimensions 
between the treatment and the placebo groups as measured by the treatment x (pre- vs. post) 
MDMQ dimensions (pleasantness: F(1;44)0.52, p=0.475; wakefulness: F(1;44)1.61, p=0.211; 
calmness: F(1;42)1.15, p=0.290). Additionally, the results did not reveal any significant 
differences in the general risk attitudes between the treatment and placebo groups as measured by 
the risk-attitude scale (MTreatment = 6.04, SDTreatment = 1.87 vs. MPlacebo = 6.25, SDPlacebo = 1.45; t(45) 
= -0.42; p = 0.674). Congruently, we found no significant differences in financial risk taking 
(Mann-Whitney-U = 247.5; p = 0.539). The median switching point from the more risky lottery B 
to the less risky lottery A was earlier than expected for risk-neutral individuals in both groups, 
indicating risk-averse subjects (Web Appendix II). In sum, ATD did not have an influence on 
subjects’ mood or risk attitude / risk taking behavior. 
The pre-analysis in study 2 was analogous to that in study 1. In terms of age in years 
(MTreatment=21.51, SDTreatment=2.37 vs. MPlacebo=20.94, SDPlacebo=1.63; t(84.92-Welch)=-1.391 
p=0.168), height in cm (MTreatment=182.18, SDTreatment=7.09 vs. MPlacebo=181.94, 
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SDPlacebo=6.86; t(96)=-0.174, p=0.862), weight in kg (MTreatment=80.88, SDTreatment=12.11 vs. 
MPlacebo=79.29, SDPlacebo=13.46; t(96)=-0.615, p=0.540), monthly net income in EUR 
(MTreatment=446.15, SDTreatment=251.11 vs. MPlacebo=506.31, SDPlacebo=244.94; t(94)=1.19, 
p=0.238) or general risk attitude (MTreatment=5.80, SDTreatment=2,02 vs. MPlacebo=5.80, 
SDPlacebo=1.72; t(96)=0.00, p=1), we again did not find any significant differences between the 
treatment and placebo groups. Furthermore, we found no significant differences in quality vs. 
price orientation for chips (MTreatment=2.55, SDTreatment=0.79 vs. MPlacebo=2.52, SDPlacebo=0.90; 
t(95)=-0.18, p=0.861) and toothpaste (MTreatment=2.71, SDTreatment=0.58 vs. MPlacebo=2.73, 
SDPlacebo=0.64; t(95)=0.12, p=0.905) as well as aided brand awareness (chips p=0.987; 
toothpaste p=0.963). 
In study 3, we again found no significant differences between the subjects in the 
treatment and placebo groups in terms of height in cm (MTreatment=182.08, SDTreatment=7.19 vs. 
MPlacebo=182.84, SDPlacebo=6.57;t(49)=0.40, p=0.694), weight in kg (MTreatment=83.85, 
SDTreatment=13.33 vs. MPlacebo=84.84, SDPlacebo=14.79; t(49)=0.25, p=0.802), or monthly net 
income in EUR (MTreatment=457.69, SDTreatment=221.64 vs. MPlacebo=524.20, SDPlacebo=234.70; 
t(49)=-0.65, p=0.518). Participants in the treatment group were slightly older (MTreatment=22.54, 
SDTreatment=1.88 vs. MPlacebo=21.60, SDPlacebo=1.68; t(49)=-1.88, p=0.067) but we judge this 
small difference (less than one year) as negligible. We found no significant differences with 
respect to the consumer-related variables quality orientation versus price orientation for 
hazelnut spread (MTreatment=3.00, SDTreatment=0.93 vs. MPlacebo=3.00, SDPlacebo=0.75; t(48)=0, 
p=1), and for headphones (MTreatment=2.83, SDTreatment=1.01 vs. MPlacebo=3.18, SDPlacebo=0.73; 
t(44)=1.331, p=0.190) as well as aided brand awareness for all the products (hazelnut spread 
p=0.982; headphones p=0.490). Finally, we found no differences in the general risk attitudes 
scale (MTreatment=5.58, SDTreatment=2.16 vs. MPlacebo=5.36, SDPlacebo=1.87; t(49)=-0.38, p=0.703).  
Also in study 4, we did not detect any significant differences between the subjects in 
the treatment and placebo groups in terms of height in cm (MTreatment=181.08, SDTreatment=6.40 
10 
vs. MPlacebo=184.79, SDPlacebo=7.82;t(47)=1.39, p=0.171), weight in kg (MTreatment=81.00, 
SDTreatment=11.57 vs. MPlacebo=85.83, SDPlacebo=12.25; t(47)=1.42, p=0.162), monthly net 
income in EUR (MTreatment=603.75, SDTreatment=205.70 vs. MPlacebo=674.58, SDPlacebo=266.88; 
t(46)=1.03, p=0.308), or age in years (MTreatment=24.56, SDTreatment=2.71 vs. MPlacebo=25.04, 
SDPlacebo=2.94; t(47)=0.60, p=0.554). Relatedly, subjects across experimental groups did not 
differ significantly in terms of consumer-related variables like quality orientation versus price 
orientation for potato chips (MTreatment=2.60, SDTreatment=0.76 vs. MPlacebo=2.42, SDPlacebo=0.93; 
t(47)=-0.76, p=0.453), for ketchup (MTreatment=2.21, SDTreatment=0.78 vs. MPlacebo=2.42, 
SDPlacebo=1.02; t(46)=0.80, p=0.430), toothpaste (MTreatment=2.46, SDTreatment=0.72 vs. 
MPlacebo=2.50, SDPlacebo=0.59; t(46)=0.22, p=0.828), hazelnut spread (MTreatment=3.08, 
SDTreatment=0.70 vs. MPlacebo=3.00, SDPlacebo=0.59; t(47)=-0.43, p=0.669), or mouthwashes 
(MTreatment=2.20, SDTreatment=1.00 vs. MPlacebo=2.57, SDPlacebo=0.90; t(46)=1.33, p=0.191). 
Subjects did also not differ with respect to aided brand awareness for all tested products 
(chips p=0.639; ketchup p=1; toothpaste p=0.827, hazelnut spread p=1; mouthwashes 
p=0.722). Finally, we found no significant differences in general risk attitudes 
(MTreatment=5.68, SDTreatment=1.95 vs. MPlacebo=5.21, SDPlacebo=2.02; t(47)=-0.83, p=0.410). 
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Table A3 
STUDY 1: OBSERVED CHOICES (WITHIN-SUBJECTS DESIGN) 
 Purchase countsa (%) 
  Total Hazelnut spread Headphones Ketchup Mulled Wine 
  CSbinary CStrinary CSbinary CStrinary CSbinary CStrinary CSbinary CStrinary CSbinary CStrinary
Pla
ceb
o (
n=
24
)  
L 58 (38.16)
56 
(30.94) 
12 
(24.49)
10 
(18.87)
15 
(42.86)
12 
(36.36)
27 
(69.23)
32 
(55.17) 
4 
(13.79) 
2 
(5.41) 
M 94 (61.84)
95 
(52.49) 
37 
(75.51)
39 
(73.58)
20 
(57.14)
16 
(48.48)
12 
(30.77)
14 
(24.14) 
25 
(86.21) 
26 
(70.27)
H - 30 (16.57) - 
4 
(7.55) - 
5 
(15.15) - 
12 
(20.69) - 
9 
(24.32)
Buy 152 (31.67)
181 
(37.71) 
49 
(40.83)
53 
(44.17)
35 
(29.17)
33 
(27.50)
39 
(32.50)
58 
(48.33) 
29 
(24.17) 
37 
(30.83)
No-
Buy 
328 
(68.33)
299 
(62.29) 
71 
(59.17)
67 
(55.83)
85 
(70.83)
87 
(72.50)
81 
(67.50)
62 
(51.67) 
91 
(75.83) 
83 
(69.17)
Tre
atm
ent
 (A
TD
) (n
=2
3) 
L 33 (34.74)
39 
(41.94) 
3 
(14.29)
6 
(27.27)
12 
(40.00)
13 
(54.17)
18 
(90.00)
19 
(90.48) 
0 
(0) 
1 
(3.85) 
M 62 (65.26)
53 
(56.99) 
18 
(85.71)
16 
(72.73)
18 
(60.00)
11 
(45.83)
2 
(10.00)
1 
(4.76) 
24 
(100) 
25 
(96.15)
H - 1 (1.08) - 
0 
(0) - 
0 
(0) - 
1 
(4.76) - 
0 
(0) 
Buy 95 (20.65)
93 
(20.22) 
21 
(18.26)
22 
(19.13)
30 
(26.09)
24 
(20.87)
20 
(17.39)
21 
(18.26) 
24 
(20.87) 
26 
(22.61)
No-
Buy 
365 
(79.35)
367 
(79.78) 
94 
(81.74)
93 
(80.87)
85 
(73.91)
91 
(79.13)
95 
(82.61)
94 
(81.74) 
91 
(79.13) 
89 
(77.39)
a Each respondent contributed 40 decisions for the analysis of this table, ten in every product category (five in the binary stage 
and five in the trinary stage). 
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Table A4 
STUDY 2: OBSERVED CHOICES (BETWEEN-SUBJECTS DESIGN) 
 Purchase countsa (%) 
  Total Chips Toothpaste 
  CSbinary CStrinary CSbinary CStrinary CSbinary CStrinary 
Pla
ceb
o (
bin
ary
: n
=2
4; 
trin
ary
: n
=2
5) L 
36 
(31.86) 
5 
(3.68) 
17 
(47.22) 
4 
(7.14) 
19 
(24.68) 
1 
(1.25) 
M 77 (68.14) 
96 
(70.59) 
19 
(52.78) 
19 
(33.93) 
58 
(75.32) 
77 
(96.25) 
H - 35 (25.74) - 
33 
(58.93) - 
2 
(2.50) 
Buy 113 (47.08) 
136 
(54.40) 
36 
(30.00) 
56 
(44.80) 
77 
(64.17) 
80 
(64.00) 
No-Buy 127 (52.92) 
114 
(45.60) 
84 
(70.00) 
69 
(55.20) 
43 
(35.83) 
45 
(36.00) 
Tre
atm
ent
 (A
TD
) (b
ina
ry:
 n=
23;
 tri
nar
y: 
n=
26)
 
L 25 (28.09) 
16 
(12.70) 
14 
(48.28) 
5 
(10.42) 
11 
(18.33) 
11 
(14.10) 
M 64 (71.91) 
68 
(53.97) 
15 
(51.72) 
16 
(33.33) 
49 
(81.67) 
52 
(66.67) 
H - 42 (33.33) - 
27 
(56.25) - 
15 
(19.23) 
Buy 89 (38.7) 
126 
(48.46) 
29 
(25.22) 
48 
(36.92) 
60 
(52.17) 
78 
(60.00) 
No-Buy 141 (61.30) 
134 
(51.54) 
86 
(74.78) 
82 
(63.08) 
55 
(47.83) 
52 
(40.00) 
a Each respondent contributed ten decisions for the analysis of this table, five in every product 
category . 
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Table A5 
STUDY 3: OBSERVED CHOICES (BETWEEN-SUBJECTS DESIGN) 
Purchase counts (%) 
 Total Hazelnut spread Headphones 
 Placebo 
(n=25) 
Treatment
(ATD) 
(n=26) 
Placebo
(n=25) 
Treatment
(ATD) 
(n=26) 
Placebo
(n=25) 
Treatment 
(ATD) 
(n=26) 
L2 14 (14.29) 
21 
(30.00) 
7 
(10.77) 
20 
(40.00) 
7 
(21.21) 
1 
(5.00) 
L 36 (36.73) 
6 
(8.57) 
20 
(30.77) 
3 
(6.00) 
16 
(48.48) 
3 
(15.00) 
M 48 (48.98) 
43 
(61.43) 
38 
(58.46) 
27 
(54.00) 
10 
(30.30) 
16 
(80.00) 
Buy 98 (39.20) 
70 
(26.92) 
65 
(52.00) 
50 
(38.46) 
33 
(26.40) 
20 
(15.38) 
No-
Buy 
152 
(60.80) 
190 
(73.08) 
60 
(48.00) 
80 
(61.54) 
92 
(73.60) 
110 
(84.62) 
a Each respondent contributed ten decisions for the analysis of this table, five in every 
product category. 
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Table A6 
STUDY 4A: OBSERVED CHOICES (WITHIN-SUBJECTS DESIGN) 
 Purchase countsa (%) 
  Total Chips Ketchup Toothpaste 
  CSbinary CStrinary CSbinary CStrinary CSbinary CStrinary CSbinary CStrinary 
Pla
ceb
o (
n=
24
)  L 
135 
(37.6) 
104 
(28.97)
45 
(37.5) 
28 
(23.33)
73 
(60.83)
62 
(51.67)
17 
(14.29) 
14 
(11.76) 
M 224 (62.4) 
193 
(53.76)
75 
(62.5) 
52 
(43.33)
47 
(39.17)
41 
(34.17)
102 
(85.71) 
100 
(84.03) 
H - 62 (17.27) - 
40 
(33.33) - 
17 
(14.17) - 
5 
(4.2) 
Tre
atm
ent
 (A
TD
) (n
=2
5) L 136 (36.27) 
123 
(32.8) 
44 
(35.2) 
43 
(34.4) 
79 
(63.2) 
69 
(55.2) 
13 
(10.4) 
11 
(8.8) 
M 239 (63.73) 
188 
(50.13)
81 
(64.8) 
50 
(40) 
46 
(36.8) 
33 
(26.4) 
112 
(89.6) 
105 
(84) 
H - 64 (17.07) - 
32 
(25.6) - 
23 
(18.4) - 
9 
(7.2) 
a Each respondent contributed 30 decisions for the analysis of this table, ten in every product category 
(five in the binary stage and five in the trinary stage). 
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Web Appendix V 
ADDITIONAL ANALYSES (STUDIES 1 – 4) 
 
Analysis of Choice Deferral 
To account for the multiple observations per respondent with regard to our hypothesis about 
choice deferral in studies 1–3, we estimated mixed-effect logit models using a dependent 
binary decision variable (1=buy, 0=no buy). The models accounted for the data’s nested 
multilevel structure by including a respondent-specific random intercept together with a 
nested product group-specific random effect intercept. The independent fixed effect predictor 
was coded 1 if a subject belongs to the placebo group and 0 if belonging to the treatment 
group. In accordance with our directional hypothesis, we expected the treatment’s coefficient 
to be positive and significant, indicating that the subjects in the placebo group are less likely 
to defer product decisions. Our analyses show that this holds for study 1 results (ß = 2.57, 
one-sided p = 0.040), for study 2 results (ß=1.12, one-sided p<0.001), as well as study 3 
results (ß=2.15, one-sided p=0.044).  
 
Analysis of the Compromise Effect 
For the within-subjects designs (studies 1 and 4a) we conducted a further robustness check to 
account for multiple decisions per respondent. We averaged all the switching patterns of each 
respondent, giving us the relative frequencies of a participant’s switches from L to M after 
adding H. This measure of the within-subjects compromise effect ranges from 0 (if a participant 
did not switch at all) to 1 (if switching was observed in all decision instances). Next, we 
evaluated if the mean tendency to switch from L to M is significantly different from zero. Our 
analysis of study 1 data reveals that this is the case for the placebo group (mean difference = 
0.017 (SD = 0.043), t(23) = 1.881; p = 0.037), but not for the treatment group (mean difference 
= 0.000, (SD = 0.000) t(22) = 0; p = 1.000). The difference between both experimental groups is 
also significant (t(23-Welch) = -1.881; p = 0.037). Our analogous, analysis of study 4a reveals that 
16 
the mean tendency to switch from L to M is significantly different from zero for the placebo 
group (mean difference = 0.064 (SD = 0.080), t(23) = 3.922; p = 0.001) and also for the treatment 
group (mean difference = 0.024, (SD = 0.047) t(24) = 2.571; p = 0.017). Consistent with our 
hypotheses, the within-subjects compromise effect is significantly more pronounced in the 
placebo group compared to the treatment group (t(47) = 2.146; p = 0.037). 
As a further robustness check of studies 2 and 4b results, we used a similar approach 
as for studies 1 and 4a, but accounted for the fact that it was not possible to aggregate 
switches in a between-subjects design setting. Therefore, we averaged the M and L decisions 
of every respondent, which yielded the respondent-specific rates for choosing L and M. Next, 
we computed a respondent-specific index for the attractiveness of M over L by subtracting the 
L options’ rate from the M options’ rate. This measure is negative if a respondent—on 
average—prefers L to M, and positive if M is more often preferred to L. In accordance with 
our hypotheses, we found that option M was significantly more attractive in the trinary sets 
than in the binary sets in the placebo group in study 2 (MeanTrinary = 0.36 (0.31) vs. MeanBinary 
= 0.17 (0.44), t(47) = -1.76, p = 0.042), whereas this is not the case in the treatment group 
(MeanTrinary = 0.20 (0.28) vs. MeanBinary = 0.17 (0.37), t(47) = -0.32, p = 0.374). The same result 
holds for an equivalent analysis of the data of study 4b (placebo group: MeanTrinary = 0.62 
(0.42) vs. MeanBinary = -0.12 (0.56), t(22) = -3.64, p = 0.001; treatment group: MeanTrinary = 
0.16 (0.45) vs. MeanBinary = 0.03 (0.14), t(14.60) = -0.98, p = 0.346). 
 
Analysis of Order Effects. 
We also tested for order effects in subjects’ decisions from the earlier to the later price 
scenarios as described in Web Appendix I. For this purpose, we analyzed the development of 
the choice shares of the compromise option M as well as the no-buy option. As expected, we 
observe higher choice shares for the target option M in later scenarios as M becomes cheaper 
over time. This trend applies to both, binary and trinary sets and, therefore, does not cofound 
17 
the results interpretation. Beyond this trend, our analyses did not indicate any systematic 
effects across the different price scenarios and studies regarding subjects’ choices of the 
compromise option or the no-buy option. Likewise, we found no interaction of potential order 
effects with the ATD treatment. 
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